Report Summary
The diagnosed diabetic population in Australia is growing, and patients are continuing to struggle to reach and maintain target blood glucose levels. These market drivers, combined with a preponderance of safety concerns over currently marketed antidiabetics in recent years, means that the opportunity for new and improved pipeline candidates is lucrative.
Browse all: Healthcare Market Research Reports
Features and benefits
Highlights
Despite strong market drivers, the Australian antidiabetics market can be difficult to penetrate, with a number of leading global brands facing restrictions in approved indications and difficulties obtaining reimbursement.
With limited pipeline development in the insulin class, the major impact on growth will come from the biosimilar threat, expected to take effect in Australia from 2015. Meanwhile, glucagon-like peptide-1 will pick up market share if reimbursement difficulties can be resolved and as longer-acting molecules reach the Australian market.
Oral antidiabetics will continue to prosper, driven by a number of late-stage pipeline candidates, including a new class of sodium-dependent glucose transporter-2 inhibitors. However, the thiazolidinedione class is expected to lose market share to other oral antidiabetics with better long-term safety profiles.
OVERVIEW OF DIABETES IN AUSTRALIA
Australia-specific diabetes epidemiology
Type 1 diabetes is increasing in incidence, but overall …